Intrommune Therapeutics' Phase 1 OMEGA study demonstrates successful safety profile of innovative toothpaste-based peanut allergy treatment, with all participants tolerating their highest assigned dose.
A groundbreaking NIH-sponsored trial demonstrated 100% success rate in helping children with high-threshold peanut allergies tolerate up to three tablespoons of peanut butter through gradual exposure therapy.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.